9 results about "Vasoconstrictor Agents" patented technology

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.

A heat exchanger is disclosed for causing cryolysis of adipose tissue of a human tongue. The heat exchanger includes a body having cooling channels for circulating fluids therein. The body forms a contact surface that contacts a portion of the dorsal surface of the tongue and a portion of the base of the tongue. The heat exchanger includes a pair of side walls extending from the body and forming a pair of side contact surfaces that are dimensioned so that they contact the dorsal and lateral surfaces of the tongue in a manner so as to constrict the tongue when the contact surface is in contact with the tongue. A method of treatment for apnea using the heat exchanger and / or administering a chemical adipolysis formulation / vasoconstriction agent is also disclosed.

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.

The utility model provides a trauma hemostasis bag, which belongs to the technical field of medical instruments and comprises a fixing sheet body, a hemostasis area is formed in the middle of the fixing sheet body, an aseptic cotton layer is arranged on the lower end face of the fixing sheet body and positioned in the hemostasis area, and a plurality of liquid injection holes are formed in the middle of the fixing sheet body. The multiple liquid injection holes are located in the hemostasis area and penetrate through the fixing piece body from top to bottom, a vasoconstriction agent is dropped into the aseptic cotton layer through the liquid injection holes, an upper protection patch is pasted to the upper end face of the fixing piece body and used for covering the multiple liquid injection holes, and a lower protection patch is pasted to the lower end face of the fixing piece body and used for covering the aseptic cotton layer. According to the trauma hemostasis bag provided by the utility model, the aseptic cotton layer permeated with the vasoconstrictor is matched with the bandage to apply external pressure, so that the aim of quickly stopping bleeding is fulfilled.

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.

The proinflammatory and vasoconstrictor agent endothelin-1 (ET-1) is a pathogenic molecule involved in an array of cardiovascular diseases. Different from ET-1 signaling for vasoconstriction in large arteries, we demonstrate herein that the coronary microvasculature exhibits unique signaling mechanisms (independent of PKC, CPI-17, and intracellular calcium storage) for constriction. The pathophysiological levels of ET-1 preferentially act on the microvasculature to exert long-lasting vasoconstriction through the activation of Rho kinase after binding to the ET-1 receptor ETAR. The ETAR antagonist BQ123 only blocks but is not able to reverse the vasoconstriction to ET-1. In contrast, ROCK inhibitors (e.g., H-1152) effectively reverse arteriolar constriction to ET-1. Therefore, ROCK inhibition is a potent and specific choice for treating coronary ischemic diseases (abnormal vasoconstriction) associated with microvascular dysfunction with overproduced ET-1. ROCK inhibitors may also be used to treat microvascular diseases related to diabetic retinopathy and microvascular dysfunction from cancer therapy or immunosuppressive medications. Since H-1152 can also reduce the basal tone of the microvasculature, ROCK inhibitors are also good diagnostic agent(s) when used during angiogram or by noninvasive methods.

The present invention provides a functional peptide with a blood pressure lowering effect, a preparation method and an application. The functional peptide provided by the present invention includes a peptide segment HPHLSFM, which has biological activity and can bind to angiotensin converting enzyme (ACE). ACE can catalyze angiotensin I to generate angiotensin II, which is a strong vasoconstrictor and an activator of adrenal cortical aldosterone release. At the same time, ACE also has the ability to decompose bradykinin (BK), which can weaken the vasodilator effect of BK, thereby leading to an increase in blood pressure in the blood circulation system. Therefore, after the functional peptide is combined with ACE, it can play a role in lowering blood pressure by inhibiting the function of ACE.

A method of treating a hemorrhage with a treatment fluid includes delivering the treatment fluid to targeted vasculature including the hemorrhage to modulate blood flow to the targeted vasculature. The treatment fluid includes a viscosifying polymer, a hemostatic agent, a vasoconstrictor, or a combination thereof. A flow guide device including a cylindrical structure with a low porosity wall, wherein the flow guide device is configured to be deployed in a parent artery including ostia of targeted vasculature. The flow guide device can facility the delivery of a treatment fluid to targeted vasculature.

Disclosed herein are mutual prodrugs of cromoglicic acid and topical antiseptics, antibiotics, anti-inflammatory agents, keratin softeners, vasoconstrictors, retinoids and retinoid-like drugs and their compositions thereof, and methods for, e.g., treating disorders, and conditions by administration of the compositions. Topical and oral compositions of mutual prodrugs of cromoglicic acid, and derivatives and analogs of cromoglicic acid are also provided.